Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea

Noh, Ji Yun; Seo, Yu Bin; Yoon, Jin Gu; Seong, Hye; Hyun, Hakjun; Jacob, Louis; Lee, Nuri; Jung, Sung Ui; Park, Min Jeong; Song, Wonkeun; Yoon, Joon Shik; Lim, Chae Seung; Ryou, Jungsang; Lee, Joo Yeon; Kim, Sung Soon; Cheong, Hee Jin; Kim, Woo Joo; Yoon, Soo Young; Song, Joon Young

doi:10.3346/jkms.2020.35.e311

Cited by 34 publications

(48 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For other studies, healthy volunteer bias 19 may underestimate seroprevalence, attracting people with symptoms 26 may overestimate seroprevalence, and studies of employees, 14 , 21 , 25 , 32 , 66 grocery store clients 23 or patient cohorts 11 , 14 , 27 – 30 , 36 , 38 , 40 , 50 , 51 , 56 , 59 , 62 , 64 , 67 risk sampling bias in an unpredictable direction.…”

Section: Resultsmentioning

confidence: 99%

Infection fatality rate of COVID-19 inferred from seroprevalence data

Ioannidis

2020

Bull. World Health Organ.

362

320

View full text Add to dashboard Cite

Objective To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data. Methods I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobin (Ig) types tested (IgG, IgM, IgA). Findings I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118–500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%. Conclusion The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic.

show abstract

Section: Resultsmentioning

confidence: 99%

Infection fatality rate of COVID-19 inferred from seroprevalence data

Ioannidis

2020

Bull. World Health Organ.

362

320

View full text Add to dashboard Cite

show abstract

“…A thorough assessment of the duration of protective immunity will be critical for determining the necessary measures to prevent and respond to future waves of SARS-CoV-2 infection. Such information must be gathered widely from various locations worldwide to reflecting the unique local conditions ( Noh et al, 2020 , Stringhini et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia

Mahallawi

Al‐Zalabani

2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

“…We assumed that unvaccinated people are initially susceptible and even vaccinated individuals might become infected at a reduced rate. In South Korea, the proportion of seropositive individuals is minimal at present (estimated at 0.07%) [ 30 ], and the rate of under-reporting is relatively low [ 31 ]. Specifically, the true number of cases exceeded the reported figure by a factor of 2.6, which is relatively low compared to those in other countries [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea

Shim

2021

JCM

View full text Add to dashboard Cite

Initial supply of the coronavirus disease (COVID-19) vaccine may be limited, necessitating its effective use. Herein, an age-structured model of COVID-19 spread in South Korea is parameterized to understand the epidemiological characteristics of COVID-19. The model determines optimal vaccine allocation for minimizing infections, deaths, and years of life lost while accounting for population factors, such as country-specific age distribution and contact structure, and various levels of vaccine efficacy. A transmission-blocking vaccine should be prioritized in adults aged 20–49 years and those older than 50 years to minimize the cumulative incidence and mortality, respectively. A strategy to minimize years of life lost involves the vaccination of adults aged 40–69 years, reflecting the relatively high case-fatality rates and years of life lost in this age group. An incidence-minimizing vaccination strategy is highly sensitive to vaccine efficacy, and vaccines with lower efficacy should be administered to teenagers and adults aged 50–59 years. Consideration of age-specific contact rates and vaccine efficacy is critical to optimize vaccine allocation. New recommendations for COVID-19 vaccines under consideration by the Korean Centers for Disease Control and Prevention are mainly based on a mortality-minimizing allocation strategy.

show abstract

Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea

Cited by 34 publications

References 13 publications

Infection fatality rate of COVID-19 inferred from seroprevalence data

Infection fatality rate of COVID-19 inferred from seroprevalence data

The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia

Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea

Contact Info

Product

Resources

About